The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.
Study Type
OBSERVATIONAL
Enrollment
687
Tertiary lymphoid structures, Plasma cells, p53 and CD8+ T cells will be evaluated at tumor biopsies of patients with advanced ovarian cancer treated with chemotherapy.
Hellenic Cooperative Oncology Group
Athens, Greece
Assessment of: Tertiary Lymphoid Structures (presence, absence) in tumor biopsies
Time frame: through study completion, an average of 3 years
Plasma cells (4-tiered score)
Time frame: 3- years time frame (upon study completion)
PD-L1 score (TPS score) in tumor biopsies
Time frame: upon study completion (3 years)
CD8 cells (low : <5 cells/HPF vs high (> 5 cells/HPF) expression) in tumor biopsies
Time frame: upron study completion (3 years)
p53 (presence, absence) in tumor biopsies (immunohistochemistry)
Time frame: upon study compeltion (3 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.